Iimvavanyo zeklinikhi

Injongo: Injongo yolu phononongo kukuvavanya iprofayili ye-pharmacokinetic kunye ne-pharmacodynamic (PK-PD) ye-lispro elawulwa yi-QS-M ye-jet-free jet injector kwizifundo zaseTshayina.

Uyilo lophando kunye neendlela: Uphononongo olungahleliwe, oluyimfama oluphindwe kabini, oluphindwe kabini, oluphambeneyo lwenziwa.Kwaqeshwa amatsha-ntliziyo alishumi elinesibhozo asempilweni.I-Lispro (iiyunithi ze-0.2 / kg) yayilawulwa yi-QS-M ye-jet injector engenanaliti okanye ngepeni eqhelekileyo.Iimvavanyo ze-euglycemic clamp zeeyure ezisixhenxe zenziwa.Amavolontiya alishumi elinesibhozo (amadoda alithoba kunye nabasetyhini abalithoba) baye baqeshwa kolu phononongo.Iikhrayitheriya zokubandakanya: abantu abangatshayiyo abaneminyaka eyi-18-40 ubudala, kunye ne-index mass body (BMI) ye-17-24 kg / m2;izifundo ezineemvavanyo eziqhelekileyo ze-biochemical, uxinzelelo lwegazi, kunye ne-electrocardiograph;izifundo ezityikitye imvume enolwazi.Iikhrayitheriya zokukhutshelwa ngaphandle zazi: izifundo ezine-insulin allergies okanye enye imbali ye-allergies;abantu abanezifo ezingapheliyo ezifana nesifo seswekile, izifo zentliziyo, isibindi okanye isifo sezintso.Abantu abasebenzisa utywala nabo babengabandakanywa.Uphononongo luvunyiwe yiKomiti yeeNqobo zokuziphatha yeSibhedlele esiManyeneyo sokuQala seYunivesithi yezoNyango yaseChongqing.

Iziphumo: Indawo enkulu ephantsi kwegophe (AUCs) yoxinzelelo lwe-insulin kunye nesantya se-glucose infusion (GIR) ngexesha lemizuzu yokuqala ye-20 emva kwesitofu se-lispro nge-jet injector xa kuthelekiswa nepeni ye-insulin yabonwa (24.91 ± 15.25 vs. 12.52 ± 7.60 mg kg−1, P <0.001 ye-AUCGIR,0–20 min; 0.36 ± 0.24 vs. 0.10 ± 0.04 U min L-1, P <0.001 ye-AUCINS, 0–20 min).I-injection engenanaliti ibonise ixesha elifutshane lokufikelela kwi-insulin enkulu (37.78 ± 11.14 vs. 80.56 ± 37.18 min, P <0.001) kunye ne-GIR (73.24 ± 29.89 vs. 116.18 ± 51.89 min, P = 0.6) .Kwakungekho nantlukwano kwi-insulin epheleleyo kunye nemiphumo ye-hypoglycemic phakathi kwezixhobo ezimbini.Isiphelo: I-Lispro elawulwa yi-QS-M ye-injector engenanaliti iphumela kwi-insulin yangaphambili kunye nephezulu yokuvezwa kwe-insulin kunepeni eqhelekileyo, kunye nefuthe elikhulu lokuqala lokunciphisa i-glucose kunye namandla afanayo jikelele.